C4 Therapeutics News and Activities

C4 Therapeutics is a company listed under the stock ticker CCCC (US).

View the org chart displaying its 27 main executives

Most searched biographies at C4 Therapeutics

• Andrew Hirsch, Chief Executive Officer and Director
• Utpal Koppikar, Director
• Donna Grogan, Director

Create your alert
to follow the executive moves at C4 Therapeutics.

C4 Therapeutics has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by C4 Therapeutics

• C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights – C4 Therapeutics
• C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D. to Board of Directors – C4 Therapeutics
• C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors – C4 Therapeutics
• C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights – C4 Therapeutics
• C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader – C4 Therapeutics
• C4 Therapeutics Appoints Utpal Koppikar to Board of Directors – C4 Therapeutics
• C4 Therapeutics Announces FDA Orphan Drug Designation for CFT8634 for the Treatment of Soft Tissue Sarcoma – C4 Therapeutics
• C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022  – C4 Therapeutics
• C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights – C4 Therapeutics
• C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation Portfolio – C4 Therapeutics
• View more press releases Close

Social media about C4 Therapeutics

• C4 Therapeutics on Wikipedia, Google News & Yahoo Finance
• C4 Therapeutics on LinkedIn, X (Twitter) & YouTube